Pharsight

Drug name - Exkivity

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10227342 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(12 years from now)

US9796712 TAKEDA PHARMS USA Heteroaryl compounds for kinase inhibition
May, 2035

(12 years from now)

CN106559991B TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

CN106559991A TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3409669B1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3157916B1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3157916A4 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3409669A1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

EP3157916A1 TAKEDA PHARMS USA Heteroaryl Compounds For Kinase Inhibition
May, 2035

(12 years from now)

Drugs and Companies using MOBOCERTINIB SUCCINATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.